πŸ‡ΊπŸ‡Έ FDA
Patent

US 10011647

IL-33 antagonists and uses thereof

granted A61KA61K38/00A61K38/17

Quick answer

US patent 10011647 (IL-33 antagonists and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
36
CPC classes
A61K, A61K38/00, A61K38/17, A61K38/20, A61K39/3955